Table 4.

Selected published studies of various regimens for biliary tract cancer

Author, year [reference]	Regimen	Dose and Schedule	N	Response Rate	TCR	Median PFS, months	Median OS, months
Choi et al., 200016	Leucovorin 5-FU	25 mg/m2/day 1−5, 375 mg/m2/day 1−5, q28d	28	32.1%	–	–	6
Arroyo et al., 200125	Gemcitabine	1000 mg/m2 on D1, 8, 15 q28 days	42	36%	64%	3.9	6.5
Alberts et al., 200527	Gemcitabine 5-FU Leucovorin	1000 mg/m2 on D1, 8,15 600 mg/m2 IVP on D1 25 mg/m2 on D1, q28d	42	9.5%	23%	4.6	9.7
Riechelmann et al., 200728	Gemcitabine Capecitabine	1000 mg/m2 on D1, 8 650 mg/m2 PO BID x14d, q21d	75	29%	78%	6.2	12.7
Koeberle et al. 200829	Gemcitabine Capecitabine	1000 mg/m2 on D1,8 650 mg/m2 PO BID, D1-14	44	25%	80%	7.2	13.2
Kim et al., 200632	Gemcitabine Cisplatin	12 500 mg/m2 on D1, 8 60 mg/m2 on D1, q21d	29	34.5%	48.3%	3.0	11
Harder et al., 200633	Gemcitabine Oxaliplatin	1000 mg/m2 on D1, 8,15 100 mg/m2 on D1, 8 q28d	31	26%	71%	6.5	11
Kim et al., 200926	Gemcitabine Oxaliplatin	1000 mg/m2 on D1, 15 85 mg/m2 on D2, 16 q28d	40	15%	52.5%	4.2	8.5
Eckel et al., 200734	Gemcitabine platinum	Various	2810	22.6%	57.3%	4.1	8.2
Valle et al., 200935	Gemcitabine Gemcitabine Cisplatin	1000 mg/m2 on D1,8,15 q 28d 1000 mg/m2 on D1,8 25 mg/m2 on D1,8 q21d	206 204	16% 25.7%	71.2% 79.1%	6.5 8.4	8.3 11.7
Williams-Current study	Gemcitabine Carboplatin	1000 mg/m2 D1,8 AUC 5 D1, q 21d	48	31.1%	75.6%	7.8	10.6

5-FU, 5-fluoropyrimidine; PFS, progression-free survival; N, number of patients; OS, overall survival; TCR, tumour control rate.